Company focused on human health and Rejuvenation
An ambitious new company focused on radically extending human healthspan using epigenetic reprogramming therapies. Their long term ambition is to rejuvenate tissue throughout the whole body. However, they plan on developing intermediary products first, with the first two indications hypothesized to be ocular disease and immunosenescence. An example of the basic research they will be pursuing is mapping age dependent transcriptional and epigenetic shifts using single cell sRNA/ATACseq.
Visit website: https://www.newlimit.com/
People at NewLimit
TechCrunch interviews founders of NewLimit after it received another $40m of funding
TechCrunch - 16-May-2023
Reprogramming the epigenetics of a cell could reverse a significant amount of the functional decline that we see with ageRead more...
Coinbase CEO selling 2% of his shares to free up over $50m for longevity investments
Lifespan.io (LEAF) - 25-Oct-2022
There is a strange overlap in interests between crypto people and longevists - and long may that benefit the industry!Read more...
NewLimit, a new biotech launches to slowdown or reverse ageing
NewLimit - 12-Dec-2021
Aims to extend healthspan and cure ageing with affordable epigenetic therapiesRead more...